Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets (QUEST)

• Number of Participants for Change From Baseline for Clinical Global Impressions of Improvement (CGI-I) at Week 12 [ Time Frame: Baseline, Week 12. ] [ Designated as safety issue: No ]
  CGI-I is a 7-point physician rated scale ranging from very much improved to very much worse.
  
  
• Number of Participants for Change From Baseline for the Caregiver's Assessment of Improvement at Week 12 [ Time Frame: Baseline, Week 12. ] [ Designated as safety issue: No ]
  The caregiver's assessment improvement was a 5-point rated scale ranging from much improved to much worse to the question 'compared to the severity of your relative's condition at baseline, how much do you feel it has changed?'.
  
  
• Change From Baseline in the Participant's Assessment for Quality of Life for Alzheimer's Dementia (QoL-AD) Overall and Subscale Scores at Week 12 [ Time Frame: Baseline, Week 12. ] [ Designated as safety issue: No ]
  QoL-AD was comprised of 13 individual items, each measured on a 4-point Likert scale (ranging from 1 [poor] to 4 [excellent]). Overall QoL-AD score was the sum of the scores for the 13 individual items and ranged from 13 to 52, with higher scores indicating a higher health related quality of life.
  
  
• Change From Baseline in the Caregiver's Assessment for Quality of Life for Alzheimer's Dementia (QoL-AD) Overall and Subscale Scores at Week 12 [ Time Frame: Baseline, Week 12. ] [ Designated as safety issue: No ]
  QoL-AD was comprised of 13 individual items, each measured on a 4-point Likert scale (ranging from 1 [poor] to 4 [excellent]). Overall QoL-AD score was the sum of the scores for the 13 individual items and ranged from 13 to 52, with higher scores indicating a higher health related quality of life.
  
  

• Change in ARICEPT Dosing: Number of Participants for Time to First ARICEPT Dose Escalation [ Time Frame: Baseline to Week 12. ] [ Designated as safety issue: No ]
  The starting dose of ARICPET was 5 mg once daily (QD), which could be increased to 10 mg QD during the study.
  
  
• Change in ARICEPT Dosing: Number of Participants at Each Final Dose of ARICEPT [ Time Frame: Week 12. ] [ Designated as safety issue: No ]
  
• Number of Participants for the Physician's Assessment of Tolerance to ARICEPT at Week 12 [ Time Frame: Baseline to Week 12. ] [ Designated as safety issue: Yes ]
  The physician rated tolerance to ARICEPT as very good, good, adequate, unsatisfactory, or unevaluable.
  
  

This non-interventional study enrolled patients with mild to moderate dementia of the Alzheimer's type, who have been prescribed treatment with ARICEPT under usual clinical practice.